NCT02289456View on ClinicalTrials.gov

Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 28, 2015

Primary Completion Date

February 22, 2017

Study Completion Date

February 22, 2017

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

nab-Paclitaxel

DRUG

Carboplatin

Trial Locations (8)

13210

SUNY Upstate Medical University, Syracuse

14642

University of RochesterJames P. Wilmont Cancer Center, Rochester

15232

University of Pittsburgh, Pittsburgh

33426

University Cancer Institute, Boynton Beach

37203

Sarah Cannon Research Institute, Nashville

45267

University of Cincinnati Medical Center, Cincinnati

48202

Henry Ford Health System, Detroit

70121

Ochsner Clinic Nephrology, New Orleans

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY